S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
OTCMKTS:BPMUF

Basilea Pharmaceutica (BPMUF) Stock Forecast, Price & News

$50.00
0.00 (0.00%)
(As of 09/21/2023 ET)
Compare
Today's Range
$50.00
$50.00
50-Day Range
$50.00
$50.00
52-Week Range
$50.00
$50.00
Volume
N/A
Average Volume
N/A
Market Capitalization
$592.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BPMUF stock logo

About Basilea Pharmaceutica (OTCMKTS:BPMUF) Stock

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

BPMUF Price History

BPMUF Stock News Headlines

Basilea Pharma Submits NDA For Antibiotic Ceftobiprole
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Basilea Pharmaceutica Posts FY Profit
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Basilea Pharma Expects Net Profit In FY22
Basilea announces repayment of 2022 convertible bonds
Basilea Pharmaceutica AG
See More Headlines
Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Company Calendar

Today
9/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BPMUF
CIK
N/A
Employees
143
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$154.86 million
Cash Flow
$1.17 per share
Book Value
($1.83) per share

Miscellaneous

Free Float
N/A
Market Cap
$592.50 million
Optionable
Not Optionable
Beta
0.84

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. David Veitch (Age 58)
    Chief Exec. Officer
    Comp: $1.37M
  • Mr. Adesh Kaul (Age 49)
    Chief Financial Officer
  • Dr. Gerrit Hauck Ph.D. (Age 59)
    Chief Technology Officer
  • Dr. Laurenz Kellenberger Ph.D. (Age 56)
    Chief Scientific Officer
  • Dr. Marc Engelhardt M.D. (Age 59)
    Chief Medical Officer
  • Dr. Peer Nils Schroder
    Head of Corp. Communications & Investor Relations
  • Mr. Damian Heller (Age 57)
    Gen. Counsel & Corp. Sec.
  • Ms. Ursula Eberhardt (Age 61)
    Head of Global HR
  • Mr. Mark Jones (Age 55)
    Head of Project Management & Preclinical Devel.
  • Mr. Peter Bielmeier Ph.D. (Age 56)
    Head of Global Quality Management













BPMUF Stock - Frequently Asked Questions

Should I buy or sell Basilea Pharmaceutica stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMUF shares.
View BPMUF analyst ratings
or view top-rated stocks.

How have BPMUF shares performed in 2023?

Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of 2023. Since then, BPMUF stock has decreased by 3.8% and is now trading at $50.00.
View the best growth stocks for 2023 here
.

Are investors shorting Basilea Pharmaceutica?

Basilea Pharmaceutica saw a decline in short interest in August. As of August 31st, there was short interest totaling 276,400 shares, a decline of 9.2% from the August 15th total of 304,300 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Basilea Pharmaceutica's Short Interest
.

What is Basilea Pharmaceutica's stock symbol?

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Basilea Pharmaceutica's stock price today?

One share of BPMUF stock can currently be purchased for approximately $50.00.

How much money does Basilea Pharmaceutica make?

Basilea Pharmaceutica (OTCMKTS:BPMUF) has a market capitalization of $592.50 million and generates $154.86 million in revenue each year.

How many employees does Basilea Pharmaceutica have?

The company employs 143 workers across the globe.

Does Basilea Pharmaceutica have any subsidiaries?
The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.
Read More
How can I contact Basilea Pharmaceutica?

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The official website for the company is www.basilea.com. The company can be reached via phone at (161) 606-1111, via email at investor_relations@basilea.com, or via fax at 41-61-606-1112.

This page (OTCMKTS:BPMUF) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -